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Abstract
Background: Previous studies on cervical cancer reported a worse outcome for adenocarcinoma (AC) compared
with squamous cell carcinoma (SCC). Nevertheless, standard treatment remains identical. Insight in the impact of
histological types on biological behavior and pathological complete response rates might result in a treatment
paradigm shift.
Methods: Clinicopathological characteristics, survival rates and relapse patterns were compared between AC
(n = 36) and SCC (n = 143) cervical cancer patients. Pathological response to treatment was evaluated in the
patient subgroup treated with neo-adjuvant chemoradiation followed by surgery (NA-CRT group; n = 84).
Results: In the entire cohort, 5y Disease Specific Survival (DSS) was 97.1 and 84% for AC and SCC respectively
(p = 0.150). In the NA-CRT group 5y DSS was 100 and 75.5% for AC and SCC respectively (p = 0.059). Relapse
patterns did not differ significantly between AC and SCC in the entire cohort, or in the NA-CRT group. Adenocarcinoma
patients treated with NA-CRT showed significantly less pathological complete response compared with SCC
patients (AC = 7%, SCC = 43%, p = 0.027).
Conclusions: There were no statistically significant differences regarding relapse and DSS rates between SCC
and AC in the entire cohort, or the NA-CRT group. However, a trend to better 5y DSS of AC in the NA-CRT
group was observed. This analysis showed significant differences in treatment responses after NA-CRT: patients
with AC responded remarkably less to chemoradiation, resulting in a significantly lower pathological complete
response rate. These findings imply a need for a paradigm shift in the treatment of cervical AC patients.
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Background
In 2012, 528.000 new cases of cervical cancer were diag-
nosed worldwide. With an estimated number of 266.000
cervical cancer deaths in the same year, this accounts for
7.5% of all female cancer deaths globally [1]. About 80%
of all cervical cancers are squamous cell carcinomas
(SCC), and about 20% are adenocarcinomas (AC). Un-
usual histological variants are rare and account only for
a minority of cases [2].
While some studies reported a worse outcome in AC
[3–6], others have failed to observe this difference [7–9].
Several studies reported significantly worse survival in
patients with AC (compared to SCC) who received de-
finitive radiation (RT) or chemoradiation (CRT) [10–13].
Others suggest that AC has a worse outcome than SCC
when treated with RT compared to RT combined with
chemotherapy or surgery [14–17]. These results suggest
that AC of the cervix might be less radiosensitive than
SCC. Despite etiological, biological and prognostic dif-
ferences, a specific treatment strategy to tackle AC has
not yet been implemented [18]. To date, the recom-
mended management of cervical cancer is mostly inde-
pendent of its histological subtype but merely guided by
staging at diagnosis [18]. For early-stage cervical cancer
patients, radical hysterectomy (followed by CRT in case
of high-risk for relapse) is the main treatment approach.
Only for fertility-sparing surgery (not recommended for
patients with small cell neuroendocrine tumors, gastric
type adenocarcinoma or adenoma malignum), recom-
mendations differ between AC and SCC. For locally ad-
vanced cervical cancer patients, definitive CRT is
standard of care [18]. Definitive CRT is a 2-step process
consisting of external beam RT ± chemotherapy (if pos-
sible cisplatin) and a brachytherapeutic boost. Even with
the use of image-guided dose-intensified brachytherapy,
local relapse arising from CRT-resistant foci is high
(3y-local pelvic control rates of 73% up to 96%, depend-
ing on stage and treating center) and remains a major
cause of treatment failure [19–21]. In exchange for an
improved overall survival (OS), adding chemotherapy to
conventional RT has doubled the risk of severe acute
hematological and gastro-intestinal toxicity and tripled
platelet toxicity [22].
Triggered off by both the high local recurrence and
the toxicity rates we challenged the gold standard by in-
vestigating the role of surgery after definitive CRT [23–
25], allowing a pathological evaluation of treatment re-
sponse in this specific group of cervical cancer patients.
The goal of this retrospective analysis was to deter-
mine the clinicopathological characteristics of patients
with cervical cancer treated at a single university center
and to investigate the differences in survival and relapse
rates between AC and SCC of the cervix. These charac-
teristics, extended with pathological treatment response,
have been investigated in the subgroup of patients
treated with CRT followed by surgery.
Methods
Study population
After institutional ethics committee approval was ob-
tained (B670201628633), the medical records of FIGO
stage IA1-IVA cervical cancer patients were reviewed.
All patients were treated between 1/1/2005 and 31/12/
2015. Twenty-eight out of 207 patients were excluded
due to following reasons: treatment for recurrent disease
or metastatic disease at diagnosis (n = 9 and n = 8, re-
spectively), treatment received in another center (n = 7),
treatment interrupted according to patients’ wish (n = 1)
or general non-cervical cancer (or its treatment) related
problems (n = 3). Independent checks were performed
for patient, tumor, treatment and outcome characteris-
tics to identify and correct major reporting errors.
The patient cohort was classified according to histo-
logical type and FIGO stage: adenocarcinoma (AC)
including adenosquamous subtypes (n = 36) versus squa-
mous cell carcinoma (SCC; n = 143) and early (FIGO
stage IA to IB1) versus advanced stages (FIGO stage IB2
to IVA). Following patient data were registered: age,
smoking, histological subtype, FIGO stage and TNM
classification, tumor grade, presence or absence of lym-
phovascular space invasion (LVSI) and pelvic lymph
node status, thrombocyte count, tumor size and depth
of invasion in case of primary surgery (maximum meas-
urable distance in cm), type of treatment (including
concomitant administration of chemotherapy), date of
diagnosis, date of end of therapy, date of last follow-up,
date and localization of first relapse, date and cause of
death. Thrombocytosis was defined as a platelet count
above 450.000/μL.
Treatment, response evaluation, follow-up and relapse
pattern
Pre-treatment imaging consisted of magnetic resonance
imaging (MRI) of the pelvis and whole body 18Fluoro-
deoxyglucose positron emission tomography – com-
puted tomography (18FDG PET-CT). The following
treatment regimens were used:
1) surgery;
2) surgery + adjuvant chemoradiation (CRT);
3) neo-adjuvant chemoradiation (NA-CRT) + surgery
according to the study protocol in case of FIGO
stage IB2-IVA [25]. This group contained all
patients who were intended to undergo surgery,
including those with an inoperable tumor due to
insufficient response to NA-CRT, and is called the
NA-CRT group from this point onwards;
4) definitive CRT (surgery was never intended).
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If possible, chemotherapy (C) was administered con-
comitantly and consisted of weekly single-agent cis-
platin (40 mg/m2). RT was performed in 25 fractions
using an Intensity Modulated Arc Technique up to a)
a minimal dose (D98) of 45Gy to the whole target in
the adjuvant CRT group and b) a minimal dose (D98)
of 45Gy to the elective lymph nodes and target vol-
ume and 62/60Gy (using a simultaneously integrated
boost) to the tumor/affected lymph nodes in the
NA-CRT group (as previously described in detail)
[24–26]. From 1/2/2009 onwards, para-aortic lymph
node irradiation was performed in case of patho-
logical enlarged (lymph node with shortest axis >
10 mm or round lymph node with axis > 8 mm) or
PET-positive pelvic lymph nodes. Brachytherapy was
applied a) from stage IB2 onwards in the adjuvant
CRT group and b) in case of doubtful or positive
margins after surgery in the NA-CRT group.
Surgery consisted of type II Wertheim hysterectomy
with pelvic lymphadenectomy performed within 6 to
8 weeks after ending NA-CRT. In the NA-CRT group,
selective nodal removal was only performed in case of
pathological enlarged or PET-positive pelvic lymph
nodes on the diagnostic 18FDG PET-CT (instead of pel-
vic lymphadenectomy). After surgery in case of NA-CRT
treatment, response was categorized as: 1) pathological
complete response (pCR): no evidence for the presence
of viable tumor cells; 2) incomplete pathological re-
sponse: any amount of viable tumor cells.
Patients were followed-up weekly during treatment,
and 1 and 3 months thereafter. Follow-up was scheduled
3-monthly during the first 2 years, 6-monthly during
year 3–5 and annually thereafter.
Relapse patterns were categorized into four groups: 1)
locoregional relapse (relapse at the tumor site and pelvic
lymph nodes); 2) distant nodal relapse (relapse at distant
lymph nodes outside the pelvis, including the para-aortic,
supraclavicular and inguinal nodes); 3) non-nodal distant
relapse (peritoneal, visceral or bone metastases) and; 4)
combined (any of previous categories occurring synchron-
ously as 1st event of relapse).
Survival rate definitions
Overall survival (OS) was defined as the time from date
of histological diagnosis to either the date of death due
to any cause or the date of last follow-up. In
disease-specific survival (DSS) analysis, only deaths
caused by cervical cancer or due to a cancer-related
cause were considered as events. Disease-free survival
(DFS) was defined as the time from end of therapy to
the occurrence of relapse. Relapse was confirmed either
histologically or clinically when follow-up imaging was
highly suggestive for recurrence.
Statistical analysis
The primary goal was to compare survival rates and re-
lapse pattern between AC and SCC in the entire patient
cohort. The secondary goal was to evaluate a difference
in survival, relapse pattern and pathological treatment
response to NA-CRT between AC and SCC in the
NA-CRT group.
Data were analyzed with the R environment for
statistical computing [27]. Balanced patient character-
istics were tested with nonparametric Wilcoxon tests
for equality of means, and Pearson’s chi-square tests
for equality of proportions [28, 29]. Kaplan-Meier
curves were applied to estimate overall survival (OS),
disease-specific survival (DSS) and disease-free sur-
vival (DFS) [30]. Univariate and multivariate survival
differences between Kaplan-Meier curves were evalu-
ated with the Cox proportional hazards regression
and log-rank test [31]. All tests were evaluated with a
95% confidence interval.
Results
Patient and treatment characteristics
Data of 179 cervical cancer patients were analyzed, of
which 36 were AC and 143 were SCC. Median age at
diagnosis was 50 years (range 24–89); median
follow-up was 50 months (3–148). FIGO stage distri-
bution was as follows: IA = 15 (8%); IB = 71 (40%);
IIA = 6 (3%); IIB = 58 (32%); IIIA = 8 (5%); IIIB = 14
(8%); and IVA = 7 (4%). Age, follow-up period, nodal
status, depth of invasion and LVSI were similar be-
tween both groups (Table 1). Lymph node metastases
were present in 28 and 38% of AC and SCC patients
(p = 0.319) respectively. In 5 SCC patients nodal sta-
tus could not be assessed. Mean tumor size was sig-
nificantly larger for SCC (4.3 cm) than AC (3.5 cm)
(p = 0.028); ACs were more often stage IB1 (50% ver-
sus 25% for SCC; p = 0.007) and well differentiated
(31% versus 6% in SCC; p = 0.0001). Squamous cell
carcinomas were more often moderately differentiated
than AC (48% versus 25% resp.; p = 0.024). The treat-
ment regimens were not significantly different be-
tween AC and SCC (Table 2). 14/36 (39%) AC and
70/143 (49%) SCC patients were treated with
NA-CRT intent respectively (NA-CRT group). Seven
patients (all SCC) did not respond sufficiently (per-
sisting parametrial invasion) to NA-CRT and did not
undergo surgery. Apart from median follow-up (AC:
59 m versus SCC: 36 m; p = 0.033) and tumor grade
(AC were more often well differentiated: 21% versus
3%; p = 0.039 or had an unknown differentiation
grade: 50% versus 20%; p = 0.042) patient characteris-
tics in the NA-CRT group were similar between the
AC and SCC groups (Table 1).
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Table 1 Patient characteristics
n Entire Cohort Neo-Adjuvant Chemoradiation group
AC SCC p AC SCC p
36 143 14 70
Age in y; median (range) 48 (27–82) 51 (24–89) 0.196 47.5 (38–65) 57 (24–89) 0.070
Follow-up in m; median (range) 54 (7–138) 50 (3–148) 0.218 59 (7–135) 36 (7–133) 0.033
Tumor FIGO stage, n (%)
IA 1 (3) 1 (1) 0.862 0 0
IA1 0 (0) 5 (3) 0.567 0 0
IA2 0 (0) 8 (6) 0.317 0 0
IB 2 (6) 2 (1) 0.380 0 0
IB1 18 (50) 36 (25) 0.007 1 (7) 1 (1) 0.749
IB2 2 (6) 11 (8) 0.934 2 (14) 6 (9) 0.868
IIA 0 (0) 2 (1) 1 0 0
IIA1 0 (0) 1 (1) 1 0 0
IIA2 2 (6) 1 (1) 0.193 1 (7) 0 0.368
IIB 9 (25) 49 (34) 0.388 8 (57) 43 (61) 1
IIIA 0 (0) 8 (6) 0.317 0 6 (9) 0.570
IIIB 2 (6) 12 (8) 0.826 2 (14) 8 (11) 1
IVA 0 (0) 7 (5) 0.382 0 6 (9) 0.570
Tumor TNM stage, n (%)
I 21 (58) 52 (36) 0.027 2 (14) 2 (3) 0.251
II 8 (22) 33 (23) 1 7 (50) 27 (39) 0.619
III 7 (19) 50 (35) 0.113 5 (36) 34 (49) 0.557
IV 0 (0) 8 (6) 0.317 0 (0) 7 (10) 0.480
Pelvic lymph node status, n (%)
negative 26 (72) 83 (58) 0.172 11 (79) 34 (49) 0.078
positive 10 (28) 55 (38) 0.319 3 (21) 36 (51) 0.078
unknown, n (%) 0 (0) 5 (3) 0.567 0 (0) 0 (0) 1
Tumor size, cm
median (range) 3.5 (0.4–7.0) 4.3 (0.1–10.5) 0.028 4.3 (2.3–7) 5.5 (1.8–8.2) 0.056
unknown, n (%) 2 (6) 24 (17) 0.149 0 2 (3) 1
Depth invasion, cm
median (range) 1 (0.3–1.7) 0.8 (0.1–5) 0.905 – –
primary surgery, n (%) 13 (36) 46 (32) 0.801 – –
unknown, n (%) 9 (25) 14 (10) 0.031 – –
no primary surgery, n (%) 14 (39) 83 (58) 0.061 – –
Chemotherapy concomitant, n (%)
yes – – 13 (93) 62 (89) 1
no – – 1 (7) 8 (11) 1
Differentiation status, n (%)
well 11 (31) 9 (6) 0.0001 3 (21) 2 (3) 0.039
moderate 9 (25) 68 (48) 0.024 3 (21) 32 (46) 0.166
poor 7 (19) 43 (30) 0.288 1 (8) 22 (32) 0.126
unknown 9 (25) 23 (16) 0.315 7 (50) 14 (20) 0.043
LVSI, n(%)
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Outcome
Survival
Thirty-nine deaths were reported, 3 in the AC group
and 36 in the SCC, resulting in a 5y OS rate of 94.4 and
73.2% (p = 0.034) respectively. The 5y OS rate for early
(FIGO stage IA to IB1) AC and SCC was 100 and 89.4%
(p = 0.408) respectively. The 5y OS for advanced (FIGO
stage IB2 to IVA) AC and SCC was 87.5 and 63.1% re-
spectively (p = 0.120). The SCC group showed more
non-disease-specific deaths (14/36, 39% of all SCC
deaths) compared to the AC group (0/3) (Table 1). Al-
though this difference was not statistically significant (p
= 0.107), we preferred using DSS to correct for this ran-
dom effect. Both FIGO (5-y DSS is 94.7, 88, 64.1 and
28.6% in FIGO stage I, II, III and IV respectively) and
TNM stage (5-y DSS is 95.3, 92.2, 77.2 and 41.7% in
TNM stage I, II, III and IV respectively) had an impact
on 5y DSS (Fig. 1a and b). The estimated 5y DSS in the
entire cohort, AC and SCC group amounted 86.8, 97.1
and 84.0% respectively (Fig. 1c), (p = 0.150). The esti-
mated 5y DSS did not differ significantly between AC
and SCC in both the early and advanced stage cohort
(AC/SCC: early 100%/93.3% and advanced 93.3%/78.6%;
p = 0.847/0.232) (Fig. 1d and e).
Five-year DSS amounted 79.8% in the overall NA-CRT
group (n = 84), and it was 100 and 75.5% (p = 0.060) for
the AC (n = 14) and SCC patients (n = 70) in this group
respectively (Fig. 1f ).
The estimated 5-year DFS rates were 73.8 and 79.2%
(p = 0.809) in the entire cohort for the AC and SCC
group respectively. The estimated 5-year DFS rates were
61.5 and 72.3% (p = 0.558) in the NA-CRT group for AC
and SCC respectively (Fig. 2a and b).
Pathological complete response rates in the NA-CRT group
Seventy-seven patients treated with NA-CRT intent
were operated upon. A pCR was obtained in 7% (1/14)
and 43% (27/63) of the AC and SCC patients respect-
ively (p = 0.027). This difference remained statistically
significant when all non-operated tumors (n = 7, all
SCC) were considered as incomplete pathological re-
sponse: 7% (1/14) versus 39% (27/70) pCR for AC and
SCC respectively (p = 0.049).
Table 1 Patient characteristics (Continued)
n Entire Cohort Neo-Adjuvant Chemoradiation group
AC SCC p AC SCC p
36 143 14 70
negative 7 (19) 14 (10) 0.187 – –
positive 11 (31) 32 (22) 0.419 – –
unknown 4 (11) 14 (10) 1 – –
no primary surgery 14 (39) 83 (58) 0.061 – –
Patient outcome, n (%)
alive/censored 33 (92) 107 (75) 0.0498 13 (93) 46 (66) 0.088
disease-specific death 2 (6) 20 (14) 0.274 0 15 (21) 0.126
other cause of death 0 (0) 14 (10) 0.107 0 8 (11) 0.406
unknown 1 (3) 2 (1) 1 1 (7) 1 (1) 0.749
AC adenocarcinoma, SCC squamous cell carcinoma, n amount, p p-value, y years, LVSI lymph vascular space invasion, significant p-values (p < 0.05) are presented
in bold
Table 2 Primary treatment by tumor histology
Treatment, n (%) AC SCC p
Surgery 10 (28) 23 (16) 0.169
Surgery + adjuvant chemoradiationab 12 (33) 36 (25) 0.437
Neo-adjuvant chemoradiationa with intent for surgeryc 14 (39) 70 (49) 0.371
Definitive chemoradiationad 0 (0) 12 (8) 0.154
Brachytherapy alonee 0 (0) 1 (1) 1
Neo-adjuvant chemotherapy + conizationf 0 (0) 1 (1) 1
AC adenocarcinoma (n = 36), SCC Squamous Cell Carcinoma (n = 143); a If possible, chemotherapy (C) was administered concomitantly and consisted of weekly
single-agent cisplatin at 40 mg/m2; b In 11/33 AC/SCC patients this includes a brachytherapeutic boost; c 7 SCC patients did not receive surgery and 1/3 AC/SCC
patients received a brachytherapeutic boost due to positive or doubtful margins; e due to co-morbidities; f fertility sparing
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Relapse
The relapse rate for the entire cohort was 8/36 (22%)
and 28/143 (20%) for AC and SCC respectively (p =
0.904) (Additional file 1: Table S1). In AC, site of first re-
lapse was 1/8 (12.5%) locoregional, 1/8 (12.5%) distant
nodal, 4/8 (50%) distant non-nodal and 2/8 (25%) a
combination of previous categories. In SCC, the site of
first relapse was 11/28 (39%) locoregional, 1/28 (4%) dis-
tant nodal, 5/28 (18%) distant non-nodal and in 11/28
(39%) of the cases a combination of previous categories.
No significant difference was found. In the NA-CRT
group, relapse rate and pattern were not significantly dif-
ferent: 5/14 (36%) and 19/70 (27%) for AC and SCC re-
spectively (p = 0.746). In AC, the site of first relapse was
0/5 (0%) locoregional, 1/5 (20%) distant nodal, 3/5 (60%)
distant non-nodal and in 1/5 (20%) of cases a combin-
ation of previous categories. In SCC, the site of first re-
lapse was 8/19 (42%) locoregional, 1/19 (5%) distant
nodal, 3/19 (16%) distant non-nodal and 7/19 (37%)
combined.
Fig. 1 a. Disease-Specific Survival (DSS) and FIGO stage: I (n = 86, 5y-DSS 94.7%), II (n = 64, 5y-DSS 88.0%), III (n = 22, 5y-DSS 64.1%) and IV
(n = 7, 5y-DSS 28.6%). (III and IV, p < 0.001). b. DSS and TNM stage: I (n = 73, 5y-DSS 95.3%), II (n = 41, 5y-DSS 92.2%), III (n = 57, 5y-DSS 77.2%) and
IV (n = 8, 5y-DSS 41.7%). (III and IV, p < 0.001). C-F. DSS and histology: c. Entire cohort: adenocarcinoma (AC): n = 36, 5y- DSS: 97.1% and Squamous
Cell Carcinoma (SCC): n = 143, 5y-DSS 84.0%; p = 0.150. d. Entire cohort; early stages: AC: n = 20, 5y-DSS: 100% and SCC: n = 52, 5y-DSS:
93.3%; p = 0.847. e. Entire cohort; advanced stages: AC: n = 16, 5y-DSS: 93.3% and SCC: n = 91, 5y-DSS: 78.6%; p = 0.232. f. NA-CRT group:
AC: n = 14, 5y-DSS: 100% and SCC: n = 70; 5y-DSS 75.5%; p = 0.059
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Uni- and multivariate analysis
Univariate analysis (Additional file 1: Table S2) showed
that lymph node involvement (HR = 2.968, p = 0.016),
tumor size (HR/cm = 1.53) and advanced FIGO stage
(HR = 3.58, p = 0.021) significantly influenced DSS.
Thrombocytosis, tumor differentiation and LVSI did not.
In multivariate analysis, only FIGO stage was observed
to have a significant impact on DSS (Additional file 1:
Table S3).
Discussion
In clinical practice, AC seems to be less responsive to
therapy and more frequently associated with earlier dis-
tant metastases. Population-based studies indicate a ris-
ing incidence of AC despite cytological screening [32].
In addition, recent studies identified certain subtypes of
non-HPV related adenocarcinoma, like gastric subtypes
with worse prognosis and higher tendency for adnexal
and distant metastases. Although a more aggressive ap-
proach of AC has often been subject of intensive re-
search, treatment of both histological types of cervical
cancer currently remains almost identical. The purpose
of this study was to test the hypothesis that both histo-
logical subtypes of cervical carcinoma have different sur-
vival, relapse patterns and response rates to treatment
and thus require tailored therapy.
There are several limitations to this study, some of
them inherent to the retrospective design, such as recall
and confounding bias. LVSI and depth invasion were
often missing in the histopathological reports. In
addition, our study reports on a heterogeneous group of
patients including all stages with different types of treat-
ment. Analyses were not corrected for treatment type.
All consecutively treated patients within the reported
period were included. Therefore, all findings are re-
stricted to this population sample. A power analysis was
conducted, and the significance tests had 80% power to
detect a difference in DSS of 12% or more between ad-
vanced AC and SCC patients. A larger sample size is
needed to detect smaller survival differences. Neverthe-
less, despite the aforementioned limitations, we observed
some very interesting and intriguing phenomena.
The study population was well balanced with the ex-
ception of FIGO stage IB1 and TNM stage 1 patients,
smaller tumors and well differentiated tumors that were
overrepresented in the AC population. Moderately dif-
ferentiated tumors were overrepresented in the SCC
population. A higher percentage of stage I [13] and well
differentiated [33] AC patients was also observed by
others. Despite the overrepresentation of FIGO stage
IB1, small and well differentiated tumors in the AC
population, we failed to observe a difference in treat-
ment regimen between AC and SCC. We assume that
this lack of difference is due to the small patient sample
size and the high amount of treatment options. If we re-
duce the treatment options to primary surgical (includ-
ing adjuvant CRT or fertility sparing neo-adjuvant
chemotherapy and conization) and primary RT intent
(including NA-CRT; definitive CRT and brachytherapy
alone) we do find more AC (22/36) than SCC (60/143)
patients primarily operated upon (p = 0.039).
In contrast to our study, several studies did report a
worse prognosis for AC (Table 3) [3, 4, 6–8, 34–38]. Three
out of 8 early AC/SCC and 9 out of 19 advanced AC/SCC
comparisons show a significant difference in survival, all
resulting in a worse outcome for AC compared to SCC.
Most of the statistically non-significant comparisons had
limited AC population sizes, limiting the power of the re-
spective tests. In addition, if the variations in the results
reflect normal study-to-study differences, then we also
would expect to find studies claiming better AC prognosis.
Yet to the best of our knowledge, we failed to find any
study reporting a significant better AC survival. In this re-
port, 5y OS of advanced stage AC is 87.5%, which is
higher than the results of most studies reported in Table 3
(5 to 87%) [39]. No significant difference in DSS was noted
between AC and SCC in the entire study cohort. However,
a trend towards a better DSS for AC was seen in the
Fig. 2 Disease-Free Survival and histology: a. Entire cohort. Adenocarcinoma (AC): n = 36; 5y-DFS 73.8% and Squamous Cell Carcinoma (SCC): n =
143, 5y-DFS 79.2%; p = 0.809. b. NA-CRT group. AC: n = 14; 5y-DFS 61.5% and SCC: n = 70, 5y-DFS 72.3%; p = 0.558. c
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NA-CRT group (p = 0.059). A possible explanation is the
more aggressive treatment used, where 78% of the ad-
vanced stage patients had surgery after NA-CRT. The ran-
domized trial of Landoni et al. compared surgery to
RT in patients with FIGO IB-IIA CC and reported
equivalent survival rates [15]. However, patients with
AC treated with hysterectomy had better DFS than
patients treated with definitive RT (66% vs 47%, p =
0.02) suggesting that AC may be more resistant to
RT [15]. Other reports confirmed that AC of the cer-
vix might be less radiosensitive than SCC [10–13, 40].
In a group of patients treated with definitive CRT,
Chen et al. [10] showed that a complete pathological
treatment response was significantly more present in
the SCC subtype compared to the adenosquamous/
AC subtypes (87.1% v s 71.4%, p = 0.018), and nearly
1/3 of the adenosquamous/AC subtypes had persistent
tumor at the cervix 3 months after completing RT.
Huang et al. [11] reported 41% residual disease in the
cervix after definitive RT for AC. Our results comple-
ment these findings in advanced stage cervical cancer,
where pCR is significantly less present in AC (AC =
Table 3 Literature Overview
Source Period Stage AC SCC Sign. AC - SCC
n 5y OS n 5yOS
Early
Hopkins et al. [4] 1970–1985 I 124 0.6 370 0.9 X −0.3
Shingleton et al. [30] 1984–1990 I 174 0.84 1136 0.84 0
Couvreur et al.a 2005–2015 IA-1B1 20 1 52 0.89 0.11
Teke et al. [8] 1996–2000 IA-IIB 33 0.77 218 0.73 0.04
Ayhan et al. [31] 1980–1997 IB 67 0.84 454 0.88 − 0.04
Eifel et al. [32] 1960–1989 IB 229 0.72 1538 0.81 X − 0.09
Nakanishi et al. [34] 1976–1995 IB 104 0.88 405 0.96 X −0.08
Galic et al. [3] 1998–2005 IB1 1094 0.85 3214 0.88 −0.03
Shimada et al. [6] 1997–2003 IB1 184 0.92 258 0.95 −0.03
Advanced
Galic et al. [3] 1998–2005 IB2 343 0.68 1701 0.69 −0.01
Shimada et al. [6] 1997–2003 IB2 39 0.76 67 0.74 0.01
Irie et al. [33] 1981–1996 IB-IIA 50 0.78 198 0.92 −0.14
Shimada et al. [6] 1997–2003 IB-IIB 280 0.87 540 0.83 0.04
Hopkins et al. [4] 1970–1985 II 40 0.47 186 0.62 X −0.15
Shingleton et al. [30] 1984–1990 II 102 0.57 1073 0.67 X −0.11
Galic et al. [3] 1998–2005 IIA 202 0.46 1488 0.58 X −0.13
Shimada et al. [6] 1997–2003 IIA 11 0.55 83 0.87 X −0.33
Galic et al. [3] 1998–2005 IIB 424 0.46 3754 0.55 X −0.09
Katanyoo et al. [7] 1980–1997 IIB 85 0.72 170 0.71 0.01
Shimada et al. [6] 1997–2003 IIB 46 0.63 132 0.79 X −0.16
Couvreur et al.a 2005–2015 IB2-IVA 16 0.88 91 0.63 0.25
Hopkins et al. [4] 1970–1985 III 25 0.08 114 0.36 X −0.28
Shingleton et al. [30] 1984–1990 III 47 0.3 672 0.4 −0.1
Galic et al. [3] 1998–2005 IIIA 80 0.16 695 0.34 X −0.18
Galic et al. [3] 1998–2005 IIIB 238 0.2 2568 0.31 X −0.11
Katanyoo et al. [7] 1995–2008 IIIB-IVA 56 0.41 112 0.47 −0.06
Shingleton et al. [30] 1984–1990 IV 41 0.05 287 0.13 −0.08
Galic et al. [3] 1998–2005 IVA 82 0.08 622 0.17 −0.09
Galic et al. [3] 1998–2005 IVB 281 0.09 959 0.06 0.04
AC adenocarcinoma, SCC Squamous cell carcinoma, n number, 5yOS 5 year overall survival period: years of enrollment of patients, Sign significance with p-value <
0.05 (all significance levels lie between 0.01 and 0.05); AC-SCC: 5y survival data AC minus 5y survival data SCC resulting in a delta value
acurrent article
Couvreur et al. BMC Cancer         (2018) 18:1101 Page 8 of 10
7%, SCC = 43%, p = 0.027). This is not due to FIGO
stage or size of the tumor since the AC group had
more favorable patient characteristics (smaller tumor
size, well differentiated, Table 1). Several potential
mechanisms of radioresistance and predictors of treat-
ment response of AC have been described before.
Cyclooxygenase-2 (COX-2) was found to be more
present in AC and COX-2 negative disease was found
in all patients responding to RT [41]. In addition, the
anti-apoptotic protein Villin1 was expressed only in
cervical AC and its presence is strongly correlated
with poorer survival [42]. Others suggested a role for
the b-catenin pathway [43]. Exploration of these pos-
sible biomarkers of treatment response will be subject
of future research.
Although pCR was low for AC in the NA-CRT group,
locoregional control was 100% and 5y DSS was high:
100% (compared to 75.5% for SCC; p = 0.059). This em-
phasizes the possible role of hysterectomy after
NA-CRT, already suggested by Eifel et al. in 1995 (albeit
in the era before concurrent chemotherapy) [44].
Conclusion
To conclude, no statistically significant differences in re-
lapse (incidence and pattern) and DSS between SCC and
AC were found. However, a trend towards a better 5y
DSS of AC in the NA-CRT group is noticed, despite a
significantly lower response to treatment (pCR). The
lower pCR rate in the AC subgroup suggests that AC is
less radiosensitive than SCC and requires a different
therapeutic strategy instead of definitive chemoradiation
alone.
Additional files
Additional file 1: Table S1. Relapse pattern in the entire cohort and
neo-adjuvant chemoradiation group. Table S2. Univariate analysis of DSS.
Table S3. Multivariate analysis of DSS. (DOCX 26 kb)
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